Kringle Pharma

Developer of recombinant protein drugs for neuro, renal and oncology disorders

placeIbaraki, Osaka, Japan calendar_todayFounded 2001 groups12 employees language kringle-pharma.com

Innovation

32 patent families (12 granted) — focus: Human necessities, Chemistry & metallurgy, Emerging technologies; filing pace accelerating. Cited 883 times.

YearFilings
20154
20164
20172
20182
20191
20201
20211
20221
20231
20243
20252
20261

Investor mix

21 investors on record; lead investors include DBJ Capital, Keio Innovation Initiative, Nissay Capital, Miraca Holdings.

Investor typeCountShare
Venture capital1048%
Other / undisclosed1152%
Coming soon